(Q37282959)

English

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer

scientific article published on 10 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Razelle Kurzrock

2

object named as

Razelle Kurzrock

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Funda Meric-Bernstam

12

object named as

Funda Meric-Bernstam

1 reference

Europe PubMed Central

19 August 2017

PMC publication ID

5

object named as

Aung Naing

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

David S Hong

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Yun Oh

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jennifer Wheler

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Les Brail

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sophie Callies

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Valérie André

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sunil K Kadam

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Aejaz Nasir

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Timothy R Holzer

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Mayer Fishman

13

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

George Simon

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

10 August 2011

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

17

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

20

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

6582-6591

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

6 September 2017

eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

6 September 2017

Taking aim at translation for tumor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

6 September 2017

Cancer genes and the pathways they control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

6 September 2017

eIF-4E expression and its role in malignancies and metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

6 September 2017

Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

6 September 2017

Antisense technologies. Improvement through novel chemical modifications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

6 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

6 September 2017

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

6 September 2017

Prediction of creatinine clearance from serum creatinine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

6 September 2017

A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

14 September 2017

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

26 June 2018

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

3 September 2018

Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

3 September 2018

Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

3 September 2018

Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5036398

3 September 2018

Identifiers

10.1158/1078-0432.CCR-11-0430

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37282959&oldid=2143632640"